Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974 May-Jun 1974;17(3):354-6. doi:10.1007/bf02586980

Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. Mar 2010;102(7):1123-8. doi:10.1038/sj.bjc.6605605

Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. May 1997;15(5):2040-9. doi:10.1200/JCO.1997.15.5.2040

Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. Sep 1996;14(9):2527-39. doi:10.1200/JCO.1996.14.9.2527

Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. Jun 2012;30(16):1941-8. doi:10.1200/JCO.2011.35.4837

Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. Dec 2012;30(35):4344-51. doi:10.1200/JCO.2012.43.8085

James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. May 2013;14(6):516-24. doi:10.1016/S1470-2045(13)70086-X

Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 07 2018;16(7):852-871. doi:10.6004/jnccn.2018.0060

Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. Nov 2013;87(4):638-45. doi:10.1016/j.ijrobp.2013.07.035

Chai CY, Tran Cao HS, Awad S, Massarweh NN. Management of Stage I Squamous Cell Carcinoma of the Anal Canal. JAMA Surg. 03 2018;153(3):209-215. doi:10.1001/jamasurg.2017.3151

Wo JY, Plastaras JP, Metz JM, et al. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys. Sep 2019;105(1):90-95. doi:10.1016/j.ijrobp.2019.04.040

Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. May 2013;86(1):27-33. doi:10.1016/j.ijrobp.2012.09.023

Meier T, Mascia A, Wolf E, Kharofa J. Dosimetric Comparison of Intensity-Modulated Proton Therapy and Volumetric-Modulated Arc Therapy in Anal Cancer Patients and the Ability to Spare Bone Marrow. Int J Part Ther. 2017;4(2):11-17. doi:10.14338/IJPT-17-00017

Ojerholm E, Kirk ML, Thompson RF, et al. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. Acta Oncol. 2015;54(8):1209-17. doi:10.3109/0284186X.2014.1002570

Anand A, Bues M, Rule WG, et al. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiother Oncol. Dec 2015;117(3):505-8. doi:10.1016/j.radonc.2015.10.027

Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. May 2011;46(3):399-424. doi:10.1080/00273171.2011.568786

Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. Apr 2008;70(5):1431-7. doi:10.1016/j.ijrobp.2007.08.074

Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. May 1991;21(1):109-22. doi:10.1016/0360-3016(91)90171-y

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. Mar 2010;76(3 Suppl):S123-9. doi:10.1016/j.ijrobp.2009.03.078

Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. Mar 2010;76(3 Suppl):S101-7. doi:10.1016/j.ijrobp.2009.05.071

Bekelman JE, Denicoff A, Buchsbaum J. Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer. J Clin Oncol. 08 2018;36(24):2461-2464. doi:10.1200/JCO.2018.77.7078

Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health. Dec 2012;9(6):504-8. doi:10.1071/SH12070

Duttenhaver JR, Shipley WU, Perrone T, et al. Protons or megavoltage X-rays as boost therapy for patients irradiated for localized prostatic carcinoma. An early phase I/II comparison. Cancer. May 1983;51(9):1599-604. doi:10.1002/1097-0142(19830501)51:9<1599::aid-cncr2820510908>3.0.co;2-o

Meyer J, Czito B, Yin FF, Willett C. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer. Jan 2007;6(5):348-56. doi:10.3816/CCC.2007.n.003

Franco P, Arcadipane F, Ragona R, et al. Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation. Cancer Invest. 2018;36(5):279-288. doi:10.1080/07357907.2018.1479413

Julie DA, Oh JH, Apte AP, et al. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncol. 2016;55(2):208-16. doi:10.3109/0284186X.2015.1043396

Lee AY, Golden DW, Bazan JG, et al. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. Int J Radiat Oncol Biol Phys. 02 2017;97(2):306-312. doi:10.1016/j.ijrobp.2016.10.010

Franco P, Ragona R, Arcadipane F, et al. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol. Jan 2017;19(1):67-75. doi:10.1007/s12094-016-1504-2

Pizzo PA. Management of Patients With Fever and Neutropenia Through the Arc of Time: A Narrative Review. Ann Intern Med. Mar 2019;170(6):389-397. doi:10.7326/M18-3192

Ilicic K, Combs SE, Schmid TE. New insights in the relative radiobiological effectiveness of proton irradiation. Radiat Oncol. Jan 2018;13(1):6. doi:10.1186/s13014-018-0954-9

Baumann BC, Mitra N, Harton JG, et al. Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. JAMA Oncol. Dec 2019;doi:10.1001/jamaoncol.2019.4889